228 related articles for article (PubMed ID: 11895967)
21. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
Sloat BR; Cui Z
Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
[TBL] [Abstract][Full Text] [Related]
22. Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice.
Uchida M; Harada T; Enkhtuya J; Kusumoto A; Kobayashi Y; Chiba S; Shyaka A; Kawamoto K
Biochem Biophys Res Commun; 2012 May; 421(2):323-8. PubMed ID: 22507985
[TBL] [Abstract][Full Text] [Related]
23. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.
Mikszta JA; Dekker JP; Harvey NG; Dean CH; Brittingham JM; Huang J; Sullivan VJ; Dyas B; Roy CJ; Ulrich RG
Infect Immun; 2006 Dec; 74(12):6806-10. PubMed ID: 17030580
[TBL] [Abstract][Full Text] [Related]
24. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
25. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
[TBL] [Abstract][Full Text] [Related]
26. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.
Campbell JD; Clement KH; Wasserman SS; Donegan S; Chrisley L; Kotloff KL
Hum Vaccin; 2007; 3(5):205-11. PubMed ID: 17881903
[TBL] [Abstract][Full Text] [Related]
27. A synthetic peptide vaccine directed against the 2ß2-2ß3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax.
Oscherwitz J; Yu F; Cease KB
J Immunol; 2010 Sep; 185(6):3661-8. PubMed ID: 20696862
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
Ndumnego OC; Köhler SM; Crafford J; van Heerden H; Beyer W
Vet Immunol Immunopathol; 2016 Oct; 178():14-21. PubMed ID: 27496738
[TBL] [Abstract][Full Text] [Related]
29. BA3338, a surface layer homology domain possessing protein augments immune response and protection efficacy of protective antigen against Bacillus anthracis in mouse model.
Kumar M; Puranik N; Varshney A; Tripathi N; Pal V; Goel AK
J Appl Microbiol; 2020 Aug; 129(2):443-452. PubMed ID: 32118336
[TBL] [Abstract][Full Text] [Related]
30. Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.
Peachman KK; Li Q; Matyas GR; Shivachandra SB; Lovchik J; Lyons RC; Alving CR; Rao VB; Rao M
Clin Vaccine Immunol; 2012 Jan; 19(1):11-6. PubMed ID: 22089245
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
[TBL] [Abstract][Full Text] [Related]
32. Detoxified lethal toxin as a potential mucosal vaccine against anthrax.
Xu Q; Zeng M
Clin Vaccine Immunol; 2008 Apr; 15(4):612-6. PubMed ID: 18256208
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of combinatorial vaccines against anthrax and plague in a murine model.
DuBois AB; Freytag LC; Clements JD
Vaccine; 2007 Jun; 25(24):4747-54. PubMed ID: 17482725
[TBL] [Abstract][Full Text] [Related]
34. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
Gaur R; Gupta PK; Banerjea AC; Singh Y
Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
[TBL] [Abstract][Full Text] [Related]
35. Stability and pre-formulation development of a plant-produced anthrax vaccine candidate.
Jones RM; Burke M; Dubose D; Chichester JA; Manceva S; Horsey A; Streatfield SJ; Breit J; Yusibov V
Vaccine; 2017 Oct; 35(41):5463-5470. PubMed ID: 28117174
[TBL] [Abstract][Full Text] [Related]
36. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
[TBL] [Abstract][Full Text] [Related]
37. Bacillus subtilis spore vaccines displaying protective antigen induce functional antibodies and protective potency.
Oh Y; Kim JA; Kim CH; Choi SK; Pan JG
BMC Vet Res; 2020 Jul; 16(1):259. PubMed ID: 32723323
[TBL] [Abstract][Full Text] [Related]
38. Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.
Feinen B; Petrovsky N; Verma A; Merkel TJ
Clin Vaccine Immunol; 2014 Apr; 21(4):580-6. PubMed ID: 24554695
[TBL] [Abstract][Full Text] [Related]
39. Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine.
Gorantala J; Grover S; Rahi A; Chaudhary P; Rajwanshi R; Sarin NB; Bhatnagar R
J Biotechnol; 2014 Apr; 176():1-10. PubMed ID: 24548460
[TBL] [Abstract][Full Text] [Related]
40. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.
Stokes MG; Titball RW; Neeson BN; Galen JE; Walker NJ; Stagg AJ; Jenner DC; Thwaite JE; Nataro JP; Baillie LW; Atkins HS
Infect Immun; 2007 Apr; 75(4):1827-34. PubMed ID: 17145938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
